Arrowhead Pharmaceuticals, Inc.: Form 10-Q for the period ended Mar 31, 2024
Filed with the SEC on May 9, 2024 and accepted by EDGAR at May 9, 2024, 16:09 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-01-01 to 2024-03-31 | $0 | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2023-10-01 to 2024-03-31 | $3.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Operating income | 3 months2024-01-01 to 2024-03-31 | −$126.2m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2023-10-01 to 2024-03-31 | −$262.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2024-01-01 to 2024-03-31 | $7.2m | us-gaap:InterestExpense |
| Interest expense | 6 months2023-10-01 to 2024-03-31 | $12.6m | us-gaap:InterestExpense |
| Income tax | 3 months2024-01-01 to 2024-03-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2023-10-01 to 2024-03-31 | −$3.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-01-01 to 2024-03-31 | −$125.3m | us-gaap:NetIncomeLoss |
| Net income | 6 months2023-10-01 to 2024-03-31 | −$258.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-01-01 to 2024-03-31 | −$1.02 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2023-10-01 to 2024-03-31 | −$2.24 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-01-01 to 2024-03-31 | −$1.02 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2023-10-01 to 2024-03-31 | −$2.24 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-01-01 to 2024-03-31 | 123,285,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2023-10-01 to 2024-03-31 | 115,307,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2023-10-01 to 2024-03-31 | −$210.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2023-10-01 to 2024-03-31 | $102.7m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-03-31 | $127.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-03-31 | $541.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-03-31 | $955.1m | us-gaap:Assets |
| Current liabilities | At period end2024-03-31 | $65.2m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2024-03-31 | $483.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-24-022215. Last ingested by Listed: Nov 4, 2026, 07:39 ET. Listed shows no prices and gives no investment advice.